Sweden
BioInvent International AB, a clinical-stage biotech firm founded in 1983 and headquartered in Sweden, is pioneering the landscape of immuno-oncology therapies by translating cancer antibody biology into innovative treatments. Leveraging its unique F.I.R.S.T™ technology platform, the company is at the forefront of discovering novel and first-in-class immuno-modulatory antibodies for cancer therapy.
Currently, BioInvent is advancing five drug candidates through six clinical programs in Phase 1/2 trials, targeting both hematological cancers and solid tumors. Beyond its robust development pipeline, the company's business model is bolstered by revenue streams from research collaborations and licensing agreements with top-tier pharmaceutical firms, alongside its fully integrated antibody manufacturing capabilities.
In its last investment round, BioInvent secured a $3.00M post-IPO equity investment in April 2023. The company's established history and strategic revenue model position it strongly for sustained growth in the biotechnology sector.
